35 citations,
January 2002 in “Scandinavian Journal of Urology and Nephrology” Finasteride reduces prostate bleeding by affecting blood vessel growth.
112 citations,
July 2012 in “The Journal of Sexual Medicine” Finasteride may cause long-lasting sexual side effects.
3 citations,
June 2018 in “International Journal of Clinical Pharmacy” Baby born healthy despite mom taking finasteride, but more research needed.
30 citations,
December 1999 in “International Journal of Dermatology” Oral ivermectin effectively cured scabies with minimal side effects, and finasteride promoted hair growth in men with hair loss.
17 citations,
June 1996 in “The Journal of Steroid Biochemistry and Molecular Biology” FCE 28260 is a stronger and longer-lasting inhibitor of 5α-reductase than finasteride, which may make it a better treatment for certain medical conditions.
May 2023 in “MQRInvestigar” A young dog with an enlarged prostate and cysts improved significantly after treatment and surgery.
56 citations,
January 2008 in “Molecular and cellular endocrinology” Two enzymes regulate androgen receptor activity, affecting treatments for androgen insufficiency and benign prostatic hyperplasia.
12 citations,
April 1995 in “Journal of Medicinal Chemistry” The new compounds moderately block a specific enzyme and strongly counteract a male hormone, suggesting potential for treating certain male-related health conditions.
9 citations,
March 1991 in “Endocrinology” Using two drugs together, Flutamide and 4-MA, is more effective for blocking male hormones than using each one alone.
39 citations,
April 2007 in “Therapeutic Drug Monitoring” Finasteride affects urinary steroid profiles and can potentially hide steroid abuse in sports drug testing.
34 citations,
January 1998 in “European Urology” Finasteride works best in 6 months and lasts 6 years.
October 2010 in “Journal of Men's Health” The conclusion is that doctors should be careful when prescribing 5α-reductase inhibitors due to possible serious side effects, and they should discuss these risks with patients.
223 citations,
December 2010 in “The Journal of Sexual Medicine” Some patients taking finasteride or dutasteride may have ongoing sexual problems and depression even after stopping the medication.
64 citations,
June 1995 in “Steroids” Inhibitors of the enzyme 5 alpha-reductase could potentially treat disorders like prostate cancer and baldness.
January 2003 in “Humana Press eBooks” Dihydrotestosterone and 5α-Reductase play a role in hair loss and prostate health, and finasteride can increase hair growth in men without affecting sperm production, but it doesn't work for postmenopausal women with hair loss.
2 citations,
April 2021 in “Canadian Journal of Urology” Five-alpha reductase inhibitors, like finasteride and dutasteride, can treat enlarged prostates, improve urination, reduce need for prostate surgery, and lower the risk of prostate cancer, but may increase the risk of higher grade prostate cancer. They can also treat male pattern baldness.
17 citations,
February 2001 in “Urologia Internationalis” Stopping alpha-blocker medication after 6-9 months is safe and effective for most patients with bladder outlet obstruction.
11 citations,
January 2018 in “Asian Journal of Andrology” Dutasteride caused more penile tissue changes than finasteride, possibly increasing erectile dysfunction risk.
82 citations,
February 1989 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” A three-month treatment with a GnRH agonist significantly lowered androgen levels and 5α-reductase activity in men with benign prostatic hyperplasia.
6 citations,
October 2007 in “Medical Hypotheses” Male pattern baldness might have evolved to help protect against prostate cancer by increasing UV radiation on the scalp.
57 citations,
January 1986 in “The Prostate” The document suggests that targeting the hormone DHT could be a more effective treatment for prostate cancer than targeting testosterone.
20 citations,
June 2015 in “Hormone Molecular Biology and Clinical Investigation” Finasteride worsens erectile dysfunction and lowers testosterone in men with enlarged prostates, unlike tamsulosin.
72 citations,
April 2008 in “The Journal of urology/The journal of urology” Dutasteride and finasteride do not significantly affect bone density, blood fats, or blood production, but slightly lower PSA levels and minimally impact sexual function in healthy young men.
6 citations,
May 2008 in “Current Opinion in Oncology” 2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.
August 2008 in “Current Opinion in Internal Medicine” In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.
116 citations,
May 1992 in “The American Journal of Medicine” Flutamide rarely causes liver toxicity in prostate cancer patients.
28 citations,
November 2003 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” The normal human prostate does not significantly affect blood DHT levels.
3 citations,
January 2018 in “Reproduction, Fertility and Development” Birth control pills increase certain receptor activities in female gerbil prostate glands and can lead to prostate changes.
March 2009 in “The Journal of Urology” Shorter PSADT after prostate surgery is linked to higher risk of death.
20 citations,
June 2007 in “Recent Patents on Endocrine, Metabolic & Immune Drug Discovery” Certain inhibitors can potentially treat prostate cancer and other hormone-dependent conditions by controlling sex hormone levels in cells.